Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Healthcare cost and utilization for chimeric antigen receptor (CAR) T‐cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis
Description:
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>B‐lineage acute lymphoblastic leukemia (B‐ALL) is the most common malignancy of childhood. With the introduction of novel cellular therapies, cost of care is a critical component and the financial burden experienced by patients and society requires evaluation.</jats:p></jats:sec><jats:sec><jats:title>Aims</jats:title><jats:p>This study aims to assess the utilization and cost of care for chimeric antigen receptor T‐cell (CAR‐T) therapy for pediatric ALL patients with commercial insurance coverage in the United States.</jats:p></jats:sec><jats:sec><jats:title>Methods and Results</jats:title><jats:p>Using de‐identified commercial insurance data from the OptumLabs® Data Warehouse, a cohort of 37 patients, aged 1‐25 years, with B‐ALL treated with CAR‐T therapy between Oct 2016 and Dec 2021 in the United States was identified. Cost was evaluated for a 90 day period encompassing CAR‐T infusion and by administration and complication characteristics. Among the 37 identified B‐ALL patients that received a CAR‐T product infusion, 14 patients were female, median age at administration was 13 years. The median 90‐day total cost was $620,500 (Mean: $589,108). Inpatient cost accounted for approximately 71% of the total cost with an average of 28 inpatient days per patient. Although inpatient cost was slightly higher in the older age group (aged 10‐25 years) and in patients with a code for cytokine release syndrome (CRS), these differences were not statistically significant.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>This real‐world cost analysis shows for the first time the encompassing cost of CAR‐T therapy for pediatric B‐ALL patients in the US with commercial insurance. This study provides a valuable benchmark that can be used to analyze the financial implications of CAR‐T therapy for pediatric B‐ALL therapy on health systems.</jats:p></jats:sec>